Bod Science Limited reported the PK study to confirm the bioavailability of Aqua Phase has been submitted for ethics approval, with approval expected within 2 weeks. Recruitment for study participants will commence
immediately once ethics approval is received. The PK study will recruit 12 subjects and will continue for 4 weeks. Results are expected in June 2023. This is the key test for the pharmaceutical application of the process technology, with a successful outcome expected to provide the base line data to support commercialisation discussions, expand Bod's value proposition, lead to new and novel delivery formats, higher margin and revenue accretion.